Tumour site, sex, and survival in colorectal cancer.
作者信息
Rosell R, Abad A
出版信息
Lancet. 2000 Sep 2;356(9232):857; author reply 858. doi: 10.1016/S0140-6736(05)73438-3.
Abstract
摘要
相似文献
1
Tumour site, sex, and survival in colorectal cancer.
Lancet. 2000 Sep 2;356(9232):857; author reply 858. doi: 10.1016/S0140-6736(05)73438-3.
2
Tumour site, sex, and survival in colorectal cancer.
Lancet. 2000 Sep 2;356(9232):857; author reply 858. doi: 10.1016/S0140-6736(05)73439-5.
3
Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability.
Clin Colorectal Cancer. 2002 Nov;2(3):146-8. doi: 10.1016/S1533-0028(11)70320-6.
4
5
Microsatellite instability in colon cancer.
N Engl J Med. 2003 Oct 30;349(18):1774-6; author reply 1774-6. doi: 10.1056/NEJM200310303491818.
6
Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Gut. 2006 Dec;55(12):1819-20. doi: 10.1136/gut.2006.105627.
7
Chemotherapy and survival in colorectal cancer patients with and without microsatellite instability: can MSI be a prognostic marker?
Gastroenterology. 2004 Aug;127(2):688-9; author reply 689-90. doi: 10.1053/j.gastro.2004.06.039.
8
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Eur J Cancer. 2009 Feb;45(3):365-73. doi: 10.1016/j.ejca.2008.07.016. Epub 2008 Aug 21.
9
p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Cancer Lett. 2004 Jul 8;210(1):101-9. doi: 10.1016/j.canlet.2004.01.006.
10
Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Clin Colorectal Cancer. 2001 Aug;1(2):104-9. doi: 10.3816/CCC.2001.n.010.
Zotero 插件